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Background: Staphylococcus aureus is the pathogen most often and prevalently involved in skin and soft tissue
infections. In recent decades outbreaks of methicillin-resistant S. aureus (MRSA) have created major problems for
skin therapy, and burn and wound care units. Topical antimicrobials are most important component of wound
infection therapy. Alternative therapies are being sought for treatment of MRSA and one area of interest is the use
of essential oils. With the increasing interest in the use and application of natural products, we screened the
potential application of terpeneless cold pressed Valencia orange oil (CPV) for topical therapy against MRSA using
an in vitro dressing model and skin keratinocyte cell culture model.
Methods: The inhibitory effect of CPV was determined by disc diffusion vapor assay for MRSA and vancomycin
intermediate-resistant S. aureus (VISA) strains. Antistaphylococcal effect of CPV in an in vitro dressing model was
tested on S. aureus inoculated tryptic soya agar plate. Bactericidal effect of CPV on MRSA and VISA infected
keratinocyte cells was examined by enumeration of extra- and intra-cellular bacterial cells at different treatment
time points. Cytotoxic effects on human skin cells was tested by adding CPV to the keratinocyte (HEK001) cells
grown in serum free KSFM media, and observed by phase-contrast microscope.
Results: CPV vapour effectively inhibited the MRSA and VISA strains in both disc diffusion vapour assay and in vitro
dressing model. Compared to untreated control addition of 0.1% CPV to MRSA infected keratinocyte decreased the
viable MRSA cells by 2 log CFU/mL in 1 h and in VISA strain 3 log CFU/mL reduction was observed in 1 h. After 3 h
viable S. aureus cells were not detected in the 0.2% CPV treatment. Bactericidal concentration of CPV did not show
any cytotoxic effect on the human skin keratinocyte cells in vitro.
Conclusions: At lower concentration addition of CPV to keratinocytes infected with MRSA and VISA rapidly killed
the bacterial cells without causing any toxic effect to the keratinocytes. Therefore, the results of this study warrant
further in vivo study to evaluate the potential of CPV as a topical antistaphylococcal agent.
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The highly adaptive S. aureus is the causative agent of a
wide variety of human infections, ranging from superficial
skin infections to deep abscesses and more serious life
threatening infections [1]. Since the 1990s, methicillin-
resistant S. aureus (MRSA) has accounted for an increas-
ing proportion of community associated infections in the
U.S. [1,2]. MRSA has become a primary cause of skin and
soft tissue infections among persons without extensive ex-
posure to healthcare settings. Data obtained from nationally* Correspondence: sricke@uark.edu
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distribution, and reproduction in any mediumrepresentative ambulatory care surveys in the U.S. show
that the infections associated with skin and soft-tissue
increased from 8.6 million in 1997 to 14.2 million in 2005
[3]. Skin and soft tissue infections (SSTIs) involve micro-
bial invasions of the primary host defence barriers epider-
mis and underlying soft tissues [4,5]. Likewise, patients
hospitalized with burn wounds are at increased risk of
developing microbial colonization and infection caused by
S. aureus. Previous studies revealed that S. aureus is the
most frequently isolated bacterial species among the other
pathogens from the burn wounds [6,7].
Generally dressings and topical antimicrobial agents
are routinely used to prevent skin and burn infectionstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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[6]. Although, a small number of antibiotics are used as
prophylactics to prevent wound infection they are not
routinely administered to burn patients due to the high
cost and the risk of adverse side effects [8]. Since, the
constant use of antibiotics select the bacterial popula-
tions including S. aureus that are resistant to multiple
antibiotics alternative therapies and new medical prac-
tices are very much needed [9–11]. One such approach
is the search of biologically active pharmacophores from
natural resources and traditional medicines [12–16].
Natural products have been investigated and utilized to
alleviate disease since early human history. Before the
“synthetic era”, 80% of all medicines were obtained from
roots, barks, leaves, flowers, seeds and fruits [17].
Numerous studies have explored the promising novel
antimicrobial candidates from plant derived essential oils
(EOs). These EOs are particularly interesting since some
oils have been used by native groups for curative purposes
in the past [18,19]. Many plants EOs have demonstrated
for antimicrobial activity against variety of bacterial patho-
gens [20,21]. One such a prominent example is tea tree oil
obtained from the Australian tree Melaleuca alternifolia.
Tea tree oil has been shown to be active against a wide
range of microorganisms including S. aureus [20,22]. In
previous studies the antimicrobial activities of EOs have
also been investigated and their actions against various
pathogens, including clinical MRSA isolates, have been
demonstrated [23–30].
Fisher et al. reported the effectiveness of citrus EOs
and vapours of lemon and the citrus EO components
citral, limonene, and linalool against a number of common
foodborne pathogens Listeria monocytenes, S. aureus,
Bacillus cereus, E. coli O157, and Campylobacter jejuni
both in vitro and on food models [31]. In our labora-
tory we have demonstrated the inhibition of Salmonella
[32], Listeria [33,34], Escherichia coli O157: H7 [35],
Campylobacter [36], and methicillin resistant S. aureus
[37] by citrus derived cold pressed Valencia orange oil, ter-
peneless Valencia orange oil, cold pressed orange terpenes,
high purity orange terpenes, d-limonene, and terpenes
from orange essence. In our previous study the in-
hibitory and cell wall lytic effect of 0.1% and 0.2%
cold pressed terpeneless Valencia orange oil (CPV)
against MRSA and VISA was demonstrated by disc
diffusion and agar dilution methods and confirmed by
genomic transcriptional profiling and electron micros-
copy [37]. With the increasing interest in the use and
application of natural antimicrobial agents for the
therapy in the present study we evaluated the poten-
tial of CPV for topical therapy against MRSA by de-
termining the antistaphylococcal effect of CPV in
dressing model and S. aureus infected keratinocyte
cell culture study.Methods
Bacterial strains
Methicillin-susceptible S. aureus strain SH1000 [38],
methicillin-resistant strains COL [39], 13136 p-m+ [40],
and N315 [41], and vancomycin intermediate-resistant
strains 13136 p-m+ V20 [42], and Mu50 [41] were used
in this study. Depending on the experimental condition
described in the following sections bacterial strains were
grown in either tryptic soya broth (TSB) or tryptic soya
agar (TSA) media (Difco Laboratories, Inc. Detroit, MI)
and incubated at 37°C for 18 h.
Orange essential oil
Commercially available terpeneless cold pressed Valencia
orange oil was obtained from Firmenich Citrus Center,
Safety Harbor, FL, USA. CPV is derived from mechanical
extraction of the orange oil which is further concen-
trated under vacuum [43]. The major components of
CPV are Linalool 20.2%, Decanal 18%, Geranial 9.1%,
α-Terpineol 5.8%, Valencene 5.2%, Neral 5%, Dodecanal
4.1%, Citronellal 3.9%, and Limonene 0.3% [36]. The most
predominant compounds are the alcohol linalool (20.2%)
followed by decanal (18%), and geranial (9.1%), the
amount of limonene is much lower at 0.3% [36].
Disc diffusion vapor assay for screening the inhibitory
effect of CPV
Disc diffusion vapor assay was carried out by the method
described by Goñi et al. [44] and Edwards-Jones et al.
[45]. Overnight cultures of the S. aureus (7 log CFU/mL)
were streaked on sterile TSA (Difco Laboratories, Inc.)
using a cotton swab dipped into the culture. The swab
was used to streak the agar plate to produce a lawn of
growth by streaking the plate in 3 different directions.
Ten μL of 100% CPV was aseptically pipetted onto sterile
6-mm paper discs (Becton Dickson, Franklin Lakes, NJ)
and subsequently the CPV impregnated paper discs were
aseptically placed in the centre of the lid of the Petri dish.
Control plates were prepared by adding 10 μL of sterile
water to the filter discs. The Petri dishes were subse-
quently sealed using parafilm and incubated at 37°C in an
inverted position. The diameters of zones of inhibitions
were measured in mm after 24 h of incubation. The assays
were carried out on three different occasions in duplicate.
In vitro dressing model study
In vitro dressing model was designed by a modification
of the method described by Edwards-Jones et al. [45].
Briefly, 10 μL aliquot of CPV (100%) was spotted in four
different areas on the sterile 10.2 x 10.2 cm, 12 ply cot-
ton gauze dressing pad (Duka Corp. Happauge, NY)
(Figure 1a). For control plates 10 μL of sterile deionized
water was spotted in the gauze dressing pad. TSA plates
were seeded with a suspension of 7 log CFU/mL of
Figure 1 Dressing model using an agar plate. (a), arrows indicate the CPV spots on gauze dressing pad; (b), complete setup of dressing
model with gauze dressing pad wrapped with bandage. Untreated control plates of S. aureus strains (c), COL; (d), Mu50; and (e), 13136 p-m+ V20.
Inhibition of S. aureus (f), COL; (g), Mu50; and (h), 13136 p-m+ V20 caused by CPV.
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and covered with single layer of sterile bandage (QMD
Medical, Quebéc, Canada) without touching the inocu-
lated agar surface. As shown in Figure 1a CPV spot-
ted gauze dressing pad was placed on the bandage by
CPV spots facing towards the inoculated agar surface
and wrapped with bandage to hold the gauze dressing
pad on the Petri plate (Figure 1b). The dressing
model Petri plates were subsequently incubated at 37°C
for 24 h and the treated plates were compared with
untreated control to identify the visible inhibition
zones. This study was carried out on three different
occasions in duplicate.Keratinocyte cell culture
Homo sapiens skin keratinocyte (HEK001) ATCC CRL-
2404™ cells were grown in keratinocyte serum free media
(K-SFM) with two additives, bovine pituitary extracts
(BPE) and human recombinant epidermal growth factor
(EGF) (Invitrogen, Carlsbad, CA). Cells were grown rou-
tinely in a 75 cm2 flask at 37°C in a 5% CO2-humidified
incubator. Ninety percent confluent cultures were trypsi-
nized, and new cultures were prepared by seeding with
105 cells/ml in 75 cm2 flasks. For cytotoxicity and infec-
tion assays, BD Falcon™ 24-well tissue culture plates (BD,
Franklin Lakes, NJ) were seeded with 105 cells/ml/well
and incubated at 37°C in a humidified 5% CO2 incubator
for 18 to 20 h to obtain a semi-confluent monolayer. Prior
to assays, the monolayers were washed and incubated with
K-SFM medium without antibiotic.Cytotoxicity assay
The MIC of CPV for the 6 S. aureus strains used in this
study was previously determined as 0.18% for the strains
13136 p-m+ and 13136 p-m+V20 and 0.2% for strains COL,
Mu50, and N315 [37]. Based on our previous results, 0.1%
and 0.2% of CPV was prepared using dimethyl sulfoxide
(DMSO) as a dispersing agent and added to the HEK001
cell monolayers and incubated for 24 h. After incubation,
the cell monolayer was observed under phase-contrast
microscope (Olympus, Japan). One set of HEK001 cell
monolayer without any treatment and another set with
equal volume of DMSO used in the CPV treatment were
used as controls. To compare a typical cytotoxicity one set
of HEK001 cell monolayer was treated with a known skin
irritant SDS (25 μg/mL) [46].
S. aureus infection assay
Adherence and invasion assays were performed using a
modified procedure derived from Harvey et al. [47].
Briefly, one loopful of overnight grown bacterial cells
were collected from TSA plates and suspended in K-SFM
media with additives. Aliquots (100 μl) of the bacter-
ial suspension, containing approximately 7 log CFU/mL
[multiplicity of infection (MOI) 1:100], were inoculated in
duplicate in a 24-well tissue culture plate containing semi-
confluent HEK001 cell monolayers. The CFUs of bacteria
were determined simultaneously by serial dilution plate
count on TSA plates. Infected monolayers were incubated
for 2 h at 37°C under a 5% CO2 humidified atmosphere to
allow the bacterial cells to adhere and infect the HEK001
cells. Infected HEK001 monolayers were washed five times
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media containing 0.1 or 0.2% CPV. For controls, infected
HEK001 monolayers were re-incubated with fresh K-SFM
medium alone or K-SFM medium with equal volume of
DMSO used in CPV treatment. After 1, 2, and 3 h of incu-
bation both controls and CPV treated HEK001 cells were
lysed with 0.1% Triton X (Sigma, St. Louis, MO) in PBS
for 15 min to detach the bacterial cells and subsequently
the lysate containing bacterial cells were diluted and viable
intra- and extra-cellular bacterial numbers were deter-
mined by counting the CFU on TSA plate. Results are
expressed as the average number of bacterial CFU from
three assays.Results and discussion
Effect of CPV vapour on S. aureus
In an effort to explore the potential use of orange EO
against antibiotic resistant S. aureus, in our earlier study
inhibitory effects and mode of action of CPV against
methicillin-susceptible strain SH1000, MRSA strains COL,
13136 p-m+, and N315, and VISA strains 13136 p-m+ V20 ,
and Mu50 were studied [37]. Compared to other tested
EOs CPV effectively inhibited all the tested S. aureus strains
[37]. Therefore, in the present study the effect of CPV
vapour on S. aureus was examined on both agar plates and
an in vitro dressing model to evaluate the potential of CPV
for topical therapy. Generally to study the antimicrobial ef-
fect of vapour, EO impregnated paper disc is placed on the
lid of Petri dish and subsequently the growth inhibition
zone is measured and used to indicate the antimicrobial
effect of EO [19,21].
In our disc diffusion CPV vapour study, growth of all
the six S. aureus strains were inhibited at different levels
(Table 1). The maximum diameter of inhibition zone
78.8± 1.8 mm was observed in VISA strain 13136 p-m+V20
followed by the MRSA strains 13136 p-m+, COL, N315,
and Mu50. The lower diameter of inhibition zone
17.8± 1.4 mm was observed in an antibiotic susceptible
strain SH1000. Similar to our observation, strain specific
variation in the growth inhibition in S. aureus wasTable 1 Inhibitory effect of terpeneless cold pressed
Valencia orange oil (CPV) against S. aureus strains
determined by a disc-diffusion vapor assay
S. aureus strain Inhibition Zone (mm)a
SH1000 17.8 ± 1.4
COL 64.0 ± 2.2
13136 p-m+ 70.2 ± 1.4
13136 p-m+V20 78.8 ± 1.8
N315 62.6 ± 2.5
Mu50 21.0 ± 2.6
a Inhibition zones are average values of three independent trials ± standard
deviation of the mean (SD, n=6).previously observed by Edwards-Jones et al. [45]. In their
study, the most effective combination of geranium and
commercial grapefruit extract Citricidal™ vapour against
MRSA did not affect the growth of antibiotic susceptible
S. aureus strain NCTC 6571 [45]. It has been previously
noted that the degree of inhibition of bacterial growth by
EOs considerably varies due to the complexity of EOs and
characteristics of bacterial strains [48]. Related to results
observed in our study Gaunt et al., [49] demonstrated the
antistaphylococcal effect of evaporated volatile com-
pounds from orange oil. In their study, agar plates inocu-
lated with S. aureus strain 8532 were exposed in a large
air-tight chamber to candle flames combined with the
volatile bactericidal compounds β-pinene and orange oil
and results showed that compared to plain candle addition
of volatile oils significantly reduced the number of S. aureus
colonies. Goñi et al. [44] also reported the susceptibility of
various strains of Gram-negative and -positive microor-
ganisms including S. aureus to vapour phase cinnamon,
clove and a mixture of cinnamon and clove EOs. In their
study they found that vapour phase of cinnamon, clove or
mixture of cinnamon and clove EOs showed better inhib-
ition of S. aureus growth than the direct contact disc dif-
fusion method [44].
Antistaphylococcal effect of CPV vapor in dressing model
Our disc diffusion vapor assay proved that the vapor
phase of the volatile components in the CPV serves as
possible source of antimicrobial agents. Therefore, we
considered assessment of the anti-staphylococcal effect of
CPV vapor in an in vitro dressing model to evaluate the
potential topical application of CPV. In this experiment
the inhibitory effect of CPV was qualitatively evaluated by
the presence or absence of inhibition zone by comparing
the test and control dressing models (Figure 1c-h). As we
observed in the disc diffusion vapor assay a similar inhibi-
tory effect was observed in the dressing model as well.
Growth of MRSA strains COL and Mu50 and VISA strain
13136 p-m+ V20 was inhibited by the vapor released from
the CPV spotted gauze dressing pad and exhibited a clear
inhibition zones on agar plates (Figure 1f-h). Our present
study has demonstrated the potential of the CPV as an
anti-MRSA agent in the vapor phase in both the disc dif-
fusion assay and the in vitro dressing model. Effectiveness
of the vapor phase EOs against microbial growth was
shown to be better than the direct contact of EOs with the
inoculated culture has already been reported in other
studies [44,50]. In an in vitro dressing model study
Edwards-Jones et al. [45] demonstrated the inhibitory ef-
fect of combination of geranium and commercial grape-
fruit extract Citricidal™ vapor against MRSA. Results of
their study concluded that EOs can be applied as a natural
anti-MRSA agent on the outer layer of the dressing with-
out disturbing the normal wound healing process.
b ca
d e
Figure 2 Effect of CPV in Homo sapiens skin keratinocyte (HEK001) ATCC CRL-2404™ cell monolayer. (a), normal HEK001 keratinocyte cell
monolayer; (b), HEK001 keratinocyte cell monolayer treated with equal volume of DMSO used in CPV treatment; (c), HEK001 keratinocyte cell
monolayer exhibiting cytotoxic effect caused by SDS (25 μg/mL); (d), HEK001 keratinocyte cell monolayer treated with 0.1% CPV; (e),
HEK001 keratinocyte cell monolayer treated with 0.2% CPV. Magnification , x400.
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Dermal exposure to either synthetic or natural chemical
substances can lead to a wide variety of skin reactions.
Therefore, it is important to evaluate the new topical
therapy agents that can potentially affect the skin cells
[51]. Skin is the first-line defense against invading patho-
gens [52], and is composed of three layers, whereas the
outermost epidermis is a squamous epithelium that
mainly consists of keratinocytes [53]. Therefore, in this
study we used keratinocyte cells as an in vitro model to
assess the effect of CPV. Since there are general con-
cerns about the toxicity and adverse effects of the plant
derived natural products on the host first we evaluated
the toxic effect of CPV on human keratinocyte cell
monolayer. In our previous study we have shown that
the MIC of CPV for the S. aureus strains used in the
present study as 0.18% for the strains 13136 p-m+ and
13136 p-m+V20 and 0.2% for strains COL, Mu50, and
N315 [37]. Therefore, to examine whether CPV has toxic
effect on keratinocyte cells, 0.1% (½ x MIC) and 0.2%
(1x MIC ) of CPV was added to the HEK001 keratinocyte
cell monolayer and subsequently at regular intervals
the cell monolayers were examined under phase-contrast
microscope for any morphological changes caused by the
toxic effect of CPV. Figure 2a is a representative picture of
normal keratinocyte cells and DMSO treated cells did
not show any toxic effect and looks similar to normalkeratinocyte cells (Figure 2b). Figure 2c represents the
cytotoxic effect caused by a known skin irritant SDS on
cell monolayer. Compared to controls (Figure 2a-c), CPV
(0.1% and 0.2%) treated keratinocyte monolayer cells did
not exhibit any toxic response even after 24 h of incuba-
tion (Figure 2d,e). Result of this observation indicated that
the concentration (0.1 and 0.2%) of CPV that has previ-
ously shown to be bactericidal for MRSA and VISA cells
did not produce any adverse effect on human epidermal
keratinocyte cells [37]. Host tolerance is one of the issues
that must be considered when evaluating natural antibac-
terial agents [54]. Many currently available antifungal and
antibacterial agent possess undesirable toxicity [16,54].
However, interestingly in our in vitro study the CPV treat-
ment on keratinocyte cells did not exhibit any toxic effect
mediated cell death in keratinocyte cells. It indicates the
potential suitability of CPV for the topical antimicrobial
treatment for dermal S. aureus infections.
Anti-staphylococcal effect of CPV in S. aureus infected
keratinocyte cells
Enumeration of total number S. aureus cells infected in
HEK001 keratinocyte monolayer indicated that addition
of CPV (0.1% or 0.2%) into the infected cells reduced
the adhesion of MRSA strain COL and VISA strain
13136p-m+V20 to the keratinocyte cells. Infected HEK001
monolayers treated with fresh K-SFM medium alone or
Table 2 Effect of CPV treatment on the total number of S. aureus infected with skin keratinocyte (HEK001) cell
monolayer









COL 7.48 ± 0.16 1 5.53 ± 0.45 2.84 ± 0.20 2.18 ± 0.42
2 5.79 ± 0.07 2.06 ± 0.38 1.60 ± 0.00
3 6.30 ± 0.07 1.98 ± 0.45 ND
13136 p-m+ V20 7.34 ± 0.11 1 5.04 ± 0.13 3.47 ± 0.20 2.62 ± 0.05
2 5.58 ± 0.06 2.83 ± 0.15 1.68 ± 0.15
3 5.88 ± 0.07 2.29 ± 0.62 ND
a Inhibition zones are average values of three independent trials ± standard deviation of the mean (SD, n=6).
ND – Not detectable.
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in CPV treatment were used as controls in this experi-
ment. We did not observe any difference between these
two controls (data not shown). Compared to the control,
CPV treated keratinocyte exhibited gradual decreases in
total numbers of attached S. aureus cells within 3 h of
treatment. After 3 h of incubation with 0.2% CPV number
of viable COL and 13136p-m+V20 cells became undetect-
able (Table 2). There are also several clinical studies
[55,56] and case reports [57,58] reporting the successful
use of EOs in treating MRSA nasal carriage or MRSA
infections. Dryden et al. [55] and Caelli et al. [59] reported
that a topical tea tree oil treatment was as effective as
standard therapy for reducing MRSA nasal colonization.
Sherry et al. demonstrated the successful use of the com-
mercial phytochemical mixture Polytoxinol™ containing the
extracts from Lemongrass, Eucalyptus, Melaleuca, Clove,
Thyme as well as B.H.T. (Butylated Hydroxy Toluene),
Triclosan (0.3%) and 95 undematured ethano (69.7%) to
treat an intractable MRSA infection of the tibia in an adult
patient [58]. Previous case studies have also demonstrated
the topical use of Eucalyptus oil extracted from the
Eucalyptus globulus leaf together with bioethanol for
MRSA wound infection. This case study has reported that
without administering any antibiotic application of 0.5 g
of the oil per day to the wound for three weeks improved
wound healing with clearing the MRSA to an undetectable
level [60]. Recently, Palaniappan and Holley showed that
natural antimicrobials carvacrol, thymol, and cinnamalde-
hyde were able to substantially decrease the MIC of
antibiotics in a diverse group of bacteria containing gen-
etic elements responsible for drug resistance [61]. They
have demonstrated the synergistic effect of carvacrol, thy-
mol, and cinnamaldehyde in the reduced MIC's of ampi-
cillin, penicillin and bacitracin against penicillin-resistant
S. aureus [61]. Thus, we speculate it is possible to use the
CPV either single topical agent or synergistically with
other antibiotics to control the S. aureus skin infections.Conclusions
MRSA is common in the U.S. and it accounts for more
than half of all soft-tissue and skin infections [2]. Surveil-
lance reports indicate that in the U.S. annual MRSA
prevalence continuously increased over the 10-year period
from 32.7% in 1998 to 53.8% in 2007 and during the
1999–2006 the percentage of S. aureus infections resistant
to methicillin increased greater than 90% in outpatients ad-
mitted to U.S. hospitals. Also, MRSA-related hospitalization
rate per 1,000 discharges doubled in 2007 [62,63]. Despite
major advances in wound and burn management in the
new millennium, infection still remains an important factor
in wound healing [6]. Novel classes are clearly needed for
MRSA, because current drug classes exhibit emerging re-
sistance. We have initiated this study as a first step towards
the investigation of potential antistaphylococcal effect of
CPV and its usage for skin infection. In this study, we have
demonstrated the antistaphylococcal effect of CPV in an
in vitro dressing model and S. aureus infected keratinocyte
cell culture study. Overall in the present study our findings
suggest that further in vivo studies of CPV are warranted
since the CPV showed the inhibition and bactericidal effect
on MRSA and VISA in the in vitro models. While, we pro-
vide interesting and valuable basic data for CPV we suggest
prior to continuing on for further studies to test the clinical
safety and efficacy of the CPV to use as topical anti-MRSA
agent comparison of the inhibitory effect of CPV with anti-
biotics currently used to treat MRSA skin infection
would provide additional valid information for the fu-
ture therapeutic applications.
In our earlier study we have reported the bacteriolytic
effect and mechanism of action of CPV in antibiotic resist-
ant S. aureus [37]. The next step in this CPV series study
focuses the comparison of the inhibitory effect of CPV
with standard antibiotic disc assay together with a quality
control strains to develop a standard evaluation method
to test the inhibitory effect of CPV on more S. aureus
strains and other pathogens.
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